This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
Subscribe To Our Newsletter & Stay Updated
